Results 141 to 150 of about 26,612 (257)

Association of Dipeptidyl Peptidase-4 Inhibitor Use with COVID-19 Mortality in Diabetic Patients: A Nationwide Cohort Study in Korea. [PDF]

J Clin Med
Park JW, Kwak MK, Park S, Heo NH, Lee EY.   +4 more
europepmc   +1 more source

The influence of dipeptidyl peptidase-4 inhibitor on the progression of type B intramural hematoma. [PDF]

Front Cardiovasc Med, 2022
Chen Q, Jiang D, Shan Z.
europepmc   +1 more source

Dipeptidyl Peptidase-4 Inhibitors

Circulation Journal, 2013
openaire   +3 more sources

Cardiovascular preventive role of thiazolidinedione in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention

Journal of Diabetes Investigation, EarlyView.
Among patients with type 2 diabetes undergoing percutaneous coronary intervention, thiazolidinedione use was independently associated with a significantly reduced risk of a composite of myocardial infarction, stroke, and all‐cause death, notably without an increased risk of admission for heart failure. ABSTRACT Background Thiazolidinediones (TZD) are a
Jinkwon Kim, Jimin Jeon, Joonsang Yoo, Minyoul Baik, Seok‐Jae Heo, Ji Woong Roh   +5 more
wiley   +1 more source

Evaluation of dipeptidyl peptidase-4 inhibitor-associated gastrointestinal symptoms using the prescription claims database. [PDF]

Sci Rep
Funabashi A, Ito H, Maeda M, Hasegawa Y, Tsukioka R, Onda M.   +5 more
europepmc   +1 more source

Collagenous Colitis Possibly Associated with Dipeptidyl Peptidase-4 Inhibitor. [PDF]

Intern Med, 2022
Takedomi H, Sakata Y, Tomonaga M, Naruse N, Yukimoto T, Akutagawa T, Tsuruoka N, Shimoda R, Kido S, Esaki M.   +9 more
europepmc   +1 more source

Sodium zirconium cyclosilicate compared with potassium restriction for hyperkalemia management in type 2 diabetes: The SILVERSTAR trial

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction To demonstrate noninferiority of continued sodium zirconium cyclosilicate therapy versus a potassium‐restricted diet in achieving normokalemia at Visit 7 (Days 28–42) in individuals with type 2 diabetes and hyperkalemia, using a noninferiority margin of −10 percentage points (one‐sided α = 0.025).
Masahide Hamaguchi, Junya Hironaka, Hiroshi Okada, Mari Yoneda, Ayaka Kobayashi, Yoshitaka Hashimoto, Aya Kitae, Noriyuki Kitagawa, Akio Kishi, Michiyo Ishii, Mai Asano, Masahiro Yamazaki, Toru Tanaka, Hanako Nakajima, Eiko Sato, Michiaki Fukui   +15 more
wiley   +1 more source

Inflammatory Bowel Disease in a Patient Returning from Colombia: Association with Dipeptidyl Peptidase 4 Inhibitor? [PDF]

Case Rep Gastroenterol
Bayoumy AB, Masclee GMC, de Boer NKH, Neefjes-Borst A, Stenvers DJ.   +4 more
europepmc   +1 more source

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Phosphate Accelerates Cellular Cholesterol Efflux in THP-1 Cells. [PDF]

Biomolecules, 2023
Komatsu T, Abe S, Nakashima S, Sasaki K, Higaki Y, Saku K, Miura SI, Uehara Y.   +7 more
europepmc   +1 more source

Insulin‐reducing effect of adding imeglimin to ongoing dipeptidyl peptidase‐4 inhibitor therapy with multiple daily insulin injections (INSPIRE study)

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction Simplifying multiple daily insulin injections (MDI) has attracted great interest in clinical practice. Although imeglimin shows good compatibility with dipeptidyl peptidase‐4 inhibitors (DPP‐4i), its effectiveness in patients treated with MDI remains unclear.
Atsushi Itsukaichi, Fukumi Yoshikawa, Manabu Saito, Ayako Fuchigami, Yoko Iwata, Genki Sato, Hiroshi Uchino, Takahisa Hirose   +7 more
wiley   +1 more source